Activation mechanisms of STAT5 by oncogenic Flt3-ITD.

Mutations in the receptor tyrosine kinase Flt3 represent a very common genetic lesion in acute myeloid leukemia (AML). Internal tandem duplication (ITD) mutations clustered in the juxtamembrane domain are the most frequent and best characterized mutations found in Flt3. Oncogenic activation of Flt3 by ITD mutations is known to activate aberrant signaling including activation of STAT5 and repression of myeloid transcription factors Pu.1 and c/EBP-alpha. However, the mechanisms of STAT5 activation by Flt3-ITD remain unclear. Using small molecule inhibitors and cell lines deficient for Src family kinases or Jak2 or Tyk2, here we show that Flt3-ITD-induced STAT5 activation is independent of Src or Jak kinases. Also, overexpression of SOCS1, an inhibitor of Jak kinases, inhibited IL-3- but not Flt3-ITD-mediated STAT5 activation. Furthermore, in vitro kinase assays revealed that STAT5 is a direct target of Flt3. Taken together, our data provide the mechanistic basis of STAT5 activation by Flt3-ITD.

[1]  E. Heiss,et al.  Identification of Y589 and Y599 in the juxtamembrane domain of Flt3 as ligand-induced autophosphorylation sites involved in binding of Src family kinases and the protein tyrosine phosphatase SHP2. , 2006, Blood.

[2]  D. Gilliland,et al.  Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD. , 2006, Blood.

[3]  L. Hennighausen,et al.  Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. , 2006, Blood.

[4]  E. Vellenga,et al.  STAT5-induced self-renewal and impaired myelopoiesis of human hematopoietic stem/progenitor cells involves down-modulation of C/EBPalpha. , 2005, Blood.

[5]  Chunaram Choudhary,et al.  AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. , 2005, Blood.

[6]  C. Miething,et al.  FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model. , 2005, Blood.

[7]  G. Morrone,et al.  Enforced expression of an Flt3 internal tandem duplication in human CD34+ cells confers properties of self-renewal and enhanced erythropoiesis. , 2005, Blood.

[8]  N. Danial,et al.  v-Abl signaling disrupts SOCS-1 function in transformed pre-B cells. , 2004, Molecular cell.

[9]  W. Alexander,et al.  The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. , 2004, Annual review of immunology.

[10]  T. Naka,et al.  Regulation of cytokine signaling by SOCS family molecules. , 2003, Trends in immunology.

[11]  M. Shibuya,et al.  Selective Cytotoxic Mechanism of GTP-14564, a Novel Tyrosine Kinase Inhibitor in Leukemia Cells Expressing a Constitutively Active Fms-like Tyrosine Kinase 3 (FLT3)* , 2003, Journal of Biological Chemistry.

[12]  Chunaram Choudhary,et al.  Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. , 2003, Blood.

[13]  Heinz Baumann,et al.  Signal transducer and activator of transcription proteins in leukemias. , 2003, Blood.

[14]  T. Naoe,et al.  Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain , 2002, Oncogene.

[15]  B. Groner,et al.  Specific DNA binding and transactivation potential of recombinant, purified Stat5 , 2001, Molecular and Cellular Endocrinology.

[16]  W. Berdel,et al.  Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. , 2000, Blood.

[17]  D. Small,et al.  Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation , 2000, Leukemia.

[18]  M. Loh,et al.  Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. , 2000, Molecular cell.

[19]  Angel W. Lee,et al.  Both Src-Dependent and -Independent Mechanisms Mediate Phosphatidylinositol 3-Kinase Regulation of Colony-Stimulating Factor 1-Activated Mitogen-Activated Protein Kinases in Myeloid Progenitors , 2000, Molecular and Cellular Biology.

[20]  A. Mui,et al.  STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells , 1999, The EMBO journal.

[21]  Jonathan A. Cooper,et al.  Src family kinases are required for integrin but not PDGFR signal transduction , 1999, The EMBO journal.

[22]  L. Wang,et al.  Stat5 is a physiological substrate of the insulin receptor. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[23]  A. Levitzki,et al.  Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor , 1996, Nature.

[24]  J. Hanke,et al.  Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor , 1996, The Journal of Biological Chemistry.

[25]  D. Levy,et al.  Roles of JAKs in activation of STATs and stimulation of c-fos gene expression by epidermal growth factor , 1996, Molecular and cellular biology.